m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0097)
| Name |
Acute myocardial infarction
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: BA41
|
||||
Full List of Target Gene(s) of This m6A-centered Disease Response
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
| Response Summary | Myocardial infarction (MI) is one of the leading causes of death. WTAP promoted myocardial I/R injury through promoting ER stress and cell apoptosis by regulating m6A modification of Cyclic AMP-dependent transcription factor ATF-4 (ATF4) mRNA. H/R effects on ER stress and apoptosis were all blocked by silencing of WTAP, promoted by WTAP overexpression, and ameliorated by administration of ER stress inhibitor, 4-PBA. | |||
| Responsed Disease | Acute myocardial infarction [ICD-11: BA41] | |||
| Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
| Target Regulation | Up regulation | |||
| Cell Process | Endoplasmic reticulum stress | |||
| Cell apoptosis | ||||
| In-vitro Model | AC16 [Human hybrid cardiomyocyte] | Normal | Homo sapiens | CVCL_4U18 |
| In-vivo Model | Left anterior descending coronary artery (LAD) was ligated for 20 minutes, followed by 48 h reperfusion. Controls underwent same procedures except LAD ligation. WTAP shRNA vector or its negative control (shNC) was injected into the left ventricular anterior wall 24 h before I/R. A pressure volume catheter was used for cardiac function assay. | |||
Scavenger receptor class F member 1 (SCARF1)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
| Response Summary | IOX1, which is an inhibitor of ALKBH5, was loaded on HSSS to form HSSS-I, which could effectively ameliorate cardiac dysfunction in acute myocardial infarction. The surface-modified bioengineered ferritin nanocage targeted the dying cells in the infarct area under the guidance of Scavenger receptor class F member 1 (SCARF1). These cells were then phagocytosed through recognition of their TfR1 receptor. | |||
| Responsed Disease | Acute myocardial infarction [ICD-11: BA41] | |||
| Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
| Cell Process | Lysosomal escape | |||
| In-vivo Model | Wild-type C57 (female, 12-16 weeks old), ALKBH5 /- mice (female and male, 12-16 weeks old), and SPF-grade SD rats (female, 180-230 g) were used to establish the AMI model.Sodium pentobarbital diluted to 10 mg/mL was used to anesthetize the mice or rat at the dose of 50 mg/kg through an intraperitoneal injection. By using a small animal ventilator with endotracheal intubation, thoracotomy was performed at the left fourth intercostal region. The heart was exposed, and the left anterior descending coronary artery (LCA) was occluded through a 6-0 silk suture that was placed 2-3 mm distal to the origin of the LCA with a slipknot. The apical region turned white, and ST segment elevation and T wave inversion of ECG showed that the AMI model was successfully established. Forty-five minutes after ischemia, the slipknot was released, and the ischemic region was reperfused. PBS (0.2 ml), HSSS (23.5 mg/kg, 0.2 ml), IOX1 (10 mg/kg, 0.2 ml), and HSSS-I (33.5 mg/kg, containing 10 mg/kg IOX1, 0.2 ml) were administered through caudal vein injection for 14 days at the frequency of one time per day. | |||
Transcriptional coactivator YAP1 (YAP1)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [5] | |||
| Response Summary | ALKBH5-mediated m6A demethylation improved the mRNA stability of YTH N6-methyladenosine RNA-binding protein 1 (YTHDF1), thereby increasing its expression, which consequently promoted the translation of Transcriptional coactivator YAP1 (YAP1).This finding suggests a novel potential therapeutic strategy for myocardial infarction cardiac regeneration. | |||
| Responsed Disease | Acute myocardial infarction [ICD-11: BA41] | |||
| Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
| Target Regulation | Up regulation | |||
| In-vivo Model | Cas9 and sgRNA were microinjected into the fertilized eggs of C57BL/6J mice, which were then transplanted to obtain positive F0 mice. The statuses of F0 mice were confirmed by PCR and sequencing. Next, positive F0 mice were mated with C57BL/6J mice to yield stable F1 generation mice. F1 and F2 transgenic mice were used in this study. | |||
Transferrin receptor protein 1 (TFRC)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
| Response Summary | IOX1, which is an inhibitor of ALKBH5, was loaded on HSSS to form HSSS-I, which could effectively ameliorate cardiac dysfunction in acute myocardial infarction. The surface-modified bioengineered ferritin nanocage targeted the dying cells in the infarct area under the guidance of Scarf1. These cells were then phagocytosed through recognition of their Transferrin receptor protein 1 (TFRC) receptor. | |||
| Responsed Disease | Acute myocardial infarction [ICD-11: BA41] | |||
| Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
| Cell Process | Lysosomal escape | |||
| In-vivo Model | Wild-type C57 (female, 12-16 weeks old), ALKBH5 /- mice (female and male, 12-16 weeks old), and SPF-grade SD rats (female, 180-230 g) were used to establish the AMI model.Sodium pentobarbital diluted to 10 mg/mL was used to anesthetize the mice or rat at the dose of 50 mg/kg through an intraperitoneal injection. By using a small animal ventilator with endotracheal intubation, thoracotomy was performed at the left fourth intercostal region. The heart was exposed, and the left anterior descending coronary artery (LCA) was occluded through a 6-0 silk suture that was placed 2-3 mm distal to the origin of the LCA with a slipknot. The apical region turned white, and ST segment elevation and T wave inversion of ECG showed that the AMI model was successfully established. Forty-five minutes after ischemia, the slipknot was released, and the ischemic region was reperfused. PBS (0.2 ml), HSSS (23.5 mg/kg, 0.2 ml), IOX1 (10 mg/kg, 0.2 ml), and HSSS-I (33.5 mg/kg, containing 10 mg/kg IOX1, 0.2 ml) were administered through caudal vein injection for 14 days at the frequency of one time per day. | |||
pri-miR-143
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
| Response Summary | METTL3 deficiency contributes to heart regeneration after MI via METTL3-pri-miR-143-(miR-143)-Yap/Ctnnd1 axis. | |||
| Responsed Disease | Acute myocardial infarction [ICD-11: BA41] | |||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Down regulation | |||
| In-vitro Model | neonatal ventricular myocytes (Mouse hearts were enzymatically digested to acquire the primary neonatal ventricular myocytes) | |||
| AC16 [Human hybrid cardiomyocyte] | Normal | Homo sapiens | CVCL_4U18 | |
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
| In total 7 item(s) under this disease | ||
| Crosstalk ID: M6ACROT03311 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | pri-miR-143 | |
| Epigenetic Regulator | Histone-lysine N-methyltransferase 2A (KMT2A) | |
| Regulated Target | Histone H3 lysine 4 trimethylation (H3K4me3) | |
| Crosstalk relationship | Histone modification → m6A | |
| Crosstalk ID: M6ACROT03312 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | Tenascin (TNC) | |
| Epigenetic Regulator | Histone-lysine N-methyltransferase 2A (KMT2A) | |
| Regulated Target | Histone H3 lysine 4 trimethylation (H3K4me3) | |
| Crosstalk relationship | Histone modification → m6A | |
| Crosstalk ID: M6ACROT03313 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | TNF receptor-associated factor 6 (TRAF6) | |
| Epigenetic Regulator | Histone-lysine N-methyltransferase 2A (KMT2A) | |
| Regulated Target | Histone H3 lysine 4 trimethylation (H3K4me3) | |
| Crosstalk relationship | Histone modification → m6A | |
| Crosstalk ID: M6ACROT03314 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | Dynamin-1-like protein (DRP1) | |
| Epigenetic Regulator | Histone-lysine N-methyltransferase 2A (KMT2A) | |
| Regulated Target | Histone H3 lysine 4 trimethylation (H3K4me3) | |
| Crosstalk relationship | Histone modification → m6A | |
| Crosstalk ID: M6ACROT05226 | ||
| m6A Regulator | Fat mass and obesity-associated protein (FTO) | |
| m6A Target | Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2a/ATP2A2) | |
| Epigenetic Regulator | Cardiac conduction regulatory RNA (CCRR) | |
| Regulated Target | FTO alpha-ketoglutarate dependent dioxygenase (FTO) | |
| Crosstalk relationship | ncRNA → m6A | |
| Crosstalk ID: M6ACROT05600 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | pri-miR-143 | |
| Epigenetic Regulator | pri-miR-143 | |
| Regulated Target | YY1-associated protein 1 (YY1AP1) | |
| Crosstalk relationship | m6A → ncRNA | |
| Crosstalk ID: M6ACROT06027 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | pri-miR-143 | |
| Epigenetic Regulator | pri-miR-143 | |
| Regulated Target | Catenin delta-1 (CTNND1) | |
| Crosstalk relationship | m6A → ncRNA | |
References